In a historic move that could transform child health outcomes across Africa, the World Health Organization (WHO) has prequalified the first-ever malaria treatment specifically formulated for newborns and young infants. The treatment—a pediatric formulation of artemether-lumefantrine, marketed as Coartem Baby—received WHO prequalification on April 24, 2026, just ahead of World Malaria Day on April 25.
For centuries, malaria has been one of Africa’s deadliest killers, stealing millions of young lives before their fifth birthday. Until now, infants suffering from malaria had to be treated with formulations designed for older children, a practice that increased the risk of incorrect dosing, dangerous side effects, and even toxic reactions. The newly prequalified treatment is the first antimalarial specifically developed for babies weighing between 2 and 5 kilograms.
Closing a Deadly Gap
WHO Director-General Dr. Tedros Adhanom Ghebreyesus welcomed the announcement with a powerful statement: “For centuries, malaria has stolen children from their parents, and health, wealth and hope from communities. But today, the story is changing. Ending malaria in our lifetime is no longer a dream—it is a real possibility.”
The prequalification designation confirms that the medicine meets international standards of quality, safety, and efficacy. This is critical because it enables public sector procurement through global health organizations, meaning governments and aid agencies can now purchase this life-saving treatment at scale for some of the world’s most vulnerable populations.
According to WHO estimates, approximately 30 million babies are born each year in malaria-endemic regions across Africa. Until now, none of them had access to a treatment designed specifically for their age group. This prequalification changes that equation entirely.
Why This Matters More Than Ever
Malaria remains one of Africa’s most persistent health crises. According to the World Malaria Report 2025, there were an estimated 282 million cases and 610,000 deaths globally in 2024—an increase from the previous year. While 47 countries have been certified malaria-free and 37 reported fewer than 1,000 cases in 2024, progress at the global level has stalled.
The challenges are numerous: drug resistance, insecticide resistance, diagnostic failures, and severe cuts in international development assistance have all eroded hard-won gains. The Iran war has further complicated global supply chains, affecting the delivery of essential medicines to conflict zones and vulnerable regions.
Yet the new treatment represents a significant counterweight to these challenges. The pediatric formulation uses a dispersible tablet that is easier to administer to infants—something that has been a persistent problem in clinical settings across the continent.
New Diagnostic Tests to Match
The timing of the announcement is significant. On April 14, 2026, WHO also prequalified three new rapid diagnostic tests (RDTs) designed to address emerging challenges with malaria detection. The new tests target a different parasite protein (pf-LDH) rather than the traditional HRP2 protein used in most existing rapid tests.
This matters because recent studies in 46 countries have documented strains of malaria parasites that have lost the gene producing the HRP2 protein—making them invisible to the most commonly used diagnostic tests. In countries in the Horn of Africa, up to 80 percent of cases have been missed as a result, leading to delayed treatment and preventable deaths.
WHO now recommends that countries switch to these alternative RDTs when more than 5 percent of cases are being missed due to pf-HRP2 deletions. This is a critical step toward ensuring accurate diagnosis and appropriate treatment across Africa.
Hope on the Horizon
Despite the many headwinds facing malaria control, the announcements mark a turning point. Twenty-five countries are now rolling out malaria vaccines, protecting millions of children. Next-generation mosquito nets now make up 84 percent of all new nets distributed globally. And since 2000, an estimated 2.3 billion malaria infections have been prevented and 14 million lives saved worldwide.
The WHO’s 2026 World Malaria Day campaign slogan—”Driven to End Malaria: Now We Can. Now We Must”—captures the dual sense of possibility and urgency that now defines the fight against this disease.
For parents in rural villages across sub-Saharan Africa, the approval of a treatment specifically designed for their youngest children is more than a medical milestone. It is a promise that their babies deserve the same chance at survival as any child anywhere in the world.